Trans-Hit Biomarkers - Unique services to TTOs and their scientists developing new biomarkers and diagnostic technologies

By: Trans-hit Biomarkers  09-12-2011

Developing new biomarkers into commercially successful products requires expertise, time and money. At Trans-Hit Biomarkers we know the challenges you face in taking your newly discovered biomarker through validation and eventually to a commercialized product. Our expertise in helping biomarker scientists to advance their biomarkers to the market is widely recognized by many well-known TTOs and key industrial players in the biomarker domain.

  • Guidance on priorities within your biomarker portfolio:

Trans-Hit Biomarkers will evaluate your biomarker programs, based on your existing experimental data, your IP, the market environment, and the regulatory requirements. This assessment will help you to decide on which technology your efforts and resources should be focused.

Biomarker Opportunity Listing: join numerous TTOs all over the world and list your biomarker out-licensing opportunities for free on our dedicated B4B-Hub for biomarkers.

Our B4B-Hub is an efficient channel to reach potential partners, with hundreds of diagnostic and pharmaceutical companies visiting on a regular basis. There is no cost, no hidden conditions and no obligation to use other Trans-Hit Biomarkers services. You keep full control (list, modify, or remove your biomarker listing) using the account management tool. It is easy to use: link your institution's web page directly to the Trans-Hit Biomarkers B4B-Hub.

  • R&D tools to quickly generate a solid, reliable and valuable proof-of-concept for successful out-licensing of your biomarker technologies:

o    Review and optimization of scientific and strategic development plans and IP strategy

o    Validation of analytical methods

Contact Trans-hit Biomarkers

Email - none provided

Print this page

Other products and services from Trans-hit Biomarkers


Trans-Hit Biomarkers - Regulatory Services

Based on the regulatory path that we will define for you, we can help you optimize each step of your research and development plan from concept to marketing strategy. Our corporate goal is to develop long-term relationships and commitments with our clients and to provide high-quality, comprehensive services and expert support.


Trans-Hit Biomarkers - Access To Animal Models

In addition, selected preclinical CRO partners have extensive knowledge and expertise in their respective fields of specialization, offering Trans-Hit Biomarkers and its clients the ability to evaluate the pertinence of their biomarkers.


Trans-Hit Biomarkers - Proteome-Hit

By combining Trans-hit Biomarkers’ access to large high-quality biospecimen collections with Caprion’s high-throughput and quantitative multiplexed mass spectrometry assays, Proteome-Hit turns the usually expensive and time-consuming clinical validation route into a fast, cost-effective and robust process.


Trans-Hit Biomarkers - Prospective Biobanking Services

Trans-Hit Biomarkers will take care of the selection, set-up and monitoring of investigator sites when multicenter prospective studies are needed for the clinical validation of new biomarkers, maintaining high-quality standards for biospecimen sampling, shipping and storage. Trans-Hit Biomarkers can help you decide which path is right for your clinical and regulatory plans, as well as help you to find retrospective samples to fit your needs.


Trans-Hit Biomarkers - Access To Human Biospecimen Collections

Assuming sample collections are of good quality and that the scientific, legal and regulatory challenges have been overcome, sample-based research should ultimately lead to the discovery and validation of new biomarkers for predictive, prognostic, surrogate and efficacy diagnostic tests.


Trans-Hit Biomarkers - ImaProteome

MALDI-Imaging Mass Spectrometry technology developed by ImaBiotech allows to generate molecular images and to quantify the distribution of molecules in complex samples such as organs, tissues and biopsies, without labeling, extraction/purification and degradation. Via automation and data processing, molecular maps of molecules can be easily generated from tissue sections collected from patients with cancer, CNS diseases, and many other diseases.